Abstract
Because of the unique clinical features of the complicated pathological conditions, multifactorial onset and spontaneous healing in the natural course of temporomandibular disorder (TMD), it is not very easy to determine the necessity of full-scale treatment. Therfore, the importance of incipient treatment of TMD was suggested. Furthermore, since most of the patients with TMD have pain as the chief complaint, there has been a tendency to select drug therapy as a choice of incipient treatment.
This study was designed to elucidate the usefulness and safety of ampiroxicam for incipient treatment of patients with TMD.
Fifty patients with TMD pain were administered 27mg of ampiroxicam once a day. The results were as follows:
1. The efficacy rate (more than moderately) was 72% in the scoring evaluation. Concomitant symptoms were observed in 3 patients, representing 6 % in incidence, but none were serious.
2. The results indicated that to use ampiroxicam as the incipient treatment was useful for relieving pain of TMD patients.
